A phase II study of gefitinib and fulvestrant in patients with advanced EGFR mutated non small cell lung cancer pretreated with reversible EGFR tyrosine kinase inhibitors - Gefitinib and fulvestrant in EGFR mutated NSCLC

Vrije Universiteit Medisch Centrum0 个研究点目标入组 48 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

暂无简介。

•1.Histologically or cytologically confirmed NSCLC locally advanced and metastatic disease stage IIIB and IV, that have an activating EGFR mutation, progressive on treatment with gefitinib or erlotinib. Patients with unknown mutation status that have exhibited a response to these agents or stable disease for at least 6 months while on treatment with gefitinib or erlotinib are also eligible
•2. At least one unidimensionally measurable lesion meeting RECIST criteria
•3. ECOG PS 0-2
•4. Age > 18 years
•5. Adequate organ function, including:
•a. Adequate bone marrow reserve: ANC > 1.5 x 109/L, platelets > 100 x 109/L.
•b. Hepatic: bilirubin <1.5 x ULN, AP, ALT, AST < 3.0 x ULN
•AP, ALT, and AST <5 xULN is acceptable if the liver has tumour involvement
•c. Renal: calculated creatinine clearance > 45 ml/min based on the Cockroft and Gault formula.
•6. Signed informed consent
•7. Male and female patients with reproductive potential must use an approved contraceptive method, if appropriate. Female patients with childbearing potential must have a negative serum pregnancy test within 14 days prior to study enrollment.
•8. Estimated life expectancy >12 weeks
•9. Patient compliance and geographical proximity that allow adequate follow up.
•10. NSCLC with an activating sensitising EGFR TK mutation as determined by using a well-validated and robust methodology.

•1. Pregnant or lactating women
•2. Patients who are poor medical risks because of non-malignant disease as well as those with active uncontrolled infection.
•3. Documented brain metastases unless the patient has completed local therapy for central nervous system metastases and has been off corticosteroids for at least two weeks before enrollment.
•4. Concomitant treatment with any other experimental drug under investigation.
•5. Known severe hypersensitivity to gefitinib or any of the excipients of the product.
•6. Presence of EGFR TK mutation reported to confer resistance to EGFR TKI: i.e., exon 20 point mutation (T790M or S768I EGFR) or exon 20 insertion as determined by using a well-validated and robust methodology.
•7. Past medical history of interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung disease.
•8. Concomitant use of known CYP 3A4 inducers such as phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort.
•9. Previous enrolment or treatment in the present study.

发起方